Abstract
For decades, mutant Ras (mut-Ras) proteins have been identified as drivers of multiple cancers including pancreatic, lung, and colon cancers. However, targeting this oncogene has been challenging and no Ras inhibitors are on the market to date. Lately several candidates targeting the downstream pathways of Ras signaling, including PI3K and Raf, were approved for cancer treatment. However, they do not present promising therapeutic effects on patients harboring Ras mutations. Recently, a variety of compounds have been reported to impair the activity of Ras, and these exciting discoveries reignite the hope for development of novel drugs targeting mut-Ras. In this article, we will review the progress made in this field and the current state-of-the-art technologies to develop Ras inhibitors. Also we will discuss the future direction of targeting Ras.
Keywords: Cancer therapy, Drug discovery, GTPase, Mutant KRas, Small molecule inhibitor, Targeting Ras.
Mini-Reviews in Medicinal Chemistry
Title:Past, Present, and Future of Targeting Ras for Cancer Therapies
Volume: 16 Issue: 5
Author(s): Zhi Tan and Shuxing Zhang
Affiliation:
Keywords: Cancer therapy, Drug discovery, GTPase, Mutant KRas, Small molecule inhibitor, Targeting Ras.
Abstract: For decades, mutant Ras (mut-Ras) proteins have been identified as drivers of multiple cancers including pancreatic, lung, and colon cancers. However, targeting this oncogene has been challenging and no Ras inhibitors are on the market to date. Lately several candidates targeting the downstream pathways of Ras signaling, including PI3K and Raf, were approved for cancer treatment. However, they do not present promising therapeutic effects on patients harboring Ras mutations. Recently, a variety of compounds have been reported to impair the activity of Ras, and these exciting discoveries reignite the hope for development of novel drugs targeting mut-Ras. In this article, we will review the progress made in this field and the current state-of-the-art technologies to develop Ras inhibitors. Also we will discuss the future direction of targeting Ras.
Export Options
About this article
Cite this article as:
Tan Zhi and Zhang Shuxing, Past, Present, and Future of Targeting Ras for Cancer Therapies, Mini-Reviews in Medicinal Chemistry 2016; 16 (5) . https://dx.doi.org/10.2174/1389557515666151001154111
DOI https://dx.doi.org/10.2174/1389557515666151001154111 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents
Current Medicinal Chemistry Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Herpesvirus / Retrovirus Chimeric Vectors
Current Gene Therapy Preparation and Characterization of a Novel Recombinant Human Parathyroid Hormone (1 – 34) Analog (Gly1-Gln26-rhPTH(1-34)) with Enhanced Biological Activity
Protein & Peptide Letters miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Anti-Insulin Receptor Antibodies in the Pathology and Therapy of Diabetes Mellitus
Current Diabetes Reviews The Tumor Suppressor Gene ARF as a Sensor of Oxidative Stress
Current Molecular Medicine Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets C-20 Cyclopropyl Vitamin D3 Analogs
Current Topics in Medicinal Chemistry Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry